The physiological functions and abuse risks of erythropoietin

This article focuses on the molecular characteristics and physiological functions of erythropoietin (EPO), systematically elaborating its core role as the sole key hormone regulating erythropoiesis in maintaining the balance of oxygen supply and demand in the body, and analyzing its therapeutic value in medicine and the pathophysiological consequences of its abuse in sports competitions.

Recent Advances
Product Information

Recent Advances

Physiological Functions and Abuse Risks of Erythropoietin

Overview
This article focuses on the molecular characteristics and physiological functions of erythropoietin (EPO), systematically elaborating its role as the sole key hormone regulating erythropoiesis in maintaining the body's oxygen supply-demand balance, and analyzing its therapeutic value in medicine and the pathophysiological consequences of its abuse in sports.

I. Molecular Characteristics and Regulation of EPO Production

Erythropoietin (EPO) is an endogenous glycoprotein hormone secreted by renal interstitial fibroblasts (in adults) and hepatocytes (during fetal development). It belongs to the type I cytokine superfamily. The human EPO gene is located on chromosome 7q21-22, encoding a mature protein composed of 165 amino acid residues with a molecular weight of approximately 30.4 kDa. Glycosylation modifications (accounting for about 30% of the molecular weight) are crucial for its in vivo stability, biological activity, and half-life. EPO production is precisely regulated by tissue oxygen partial pressure—when renal interstitial cells detect insufficient oxygen supply, hypoxia-inducible factors-1α/2α stabilize and initiate EPO gene transcription, increasing EPO synthesis and secretion.

II. Physiological Mechanisms of EPO in Regulating Erythropoiesis

EPO is the sole physiological regulator of new red blood cell production in the body. Red blood cells, as the most abundant cellular component in blood, are responsible for transporting oxygen from the lungs to tissues and returning carbon dioxide to the lungs for excretion. However, mature red blood cells lack nuclei and mitochondria, cannot divide or proliferate, and thus cannot increase in number through self-replication. Therefore, the only way the body maintains red blood cell counts is through the differentiation and maturation of hematopoietic stem cells into erythroid progenitor cells in the bone marrow.

EPO acts by binding to EPO receptors (EPOR) on the surface of erythroid progenitor cells (such as BFU-E and CFU-E). EPOR belongs to the type I cytokine receptor family and exists as a homodimer. Upon EPO binding, EPOR undergoes conformational changes, activating JAK2 tyrosine kinase, which phosphorylates tyrosine residues in the receptor's intracellular domain, initiating downstream signaling pathways such as STAT5, PI3K/AKT, and Ras/MAPK. These pathways synergistically inhibit apoptosis of erythroid progenitor cells while driving their proliferation and differentiation into proerythroblasts, basophilic erythroblasts, polychromatic erythroblasts, orthochromatic erythroblasts, and finally enucleated reticulocytes released into the bloodstream, completing erythropoiesis.

Under normal physiological conditions, human EPO secretion maintains a relatively stable level to match the normal turnover rate of red blood cells (approximately 200 billion new red blood cells per day in adults). When tissue hypoxia occurs—such as in high-altitude environments, chronic lung diseases, or anemia—EPO synthesis can increase by tens to hundreds of times, accelerating erythropoiesis to enhance blood oxygen-carrying capacity.

III. Medical Applications and Therapeutic Value of EPO

Since its first approval in 1989, recombinant human EPO (rHuEPO) has become an indispensable therapeutic drug in clinical medicine. Its primary indications include: anemia due to chronic kidney disease (particularly in end-stage renal disease patients undergoing dialysis), the most classic application of EPO; chemotherapy-induced anemia, to alleviate red blood cell reduction in cancer patients; and anemia in myelodysplastic syndromes, preterm infants, and perioperative red blood cell mobilization. Under strict medical supervision, rHuEPO dosing is precisely regulated to maintain hemoglobin levels within the target range (typically 10-12 g/dL), improving anemia symptoms while avoiding adverse effects.

IV. Abuse Risks and Pathological Consequences of EPO in Sports

Despite its clear therapeutic value in medicine, EPO has been abused as a performance-enhancing drug in sports. Athletes inject exogenous EPO to artificially increase hematocrit and hemoglobin concentration, thereby enhancing blood oxygen-carrying capacity and endurance performance—effects particularly pronounced in endurance sports such as long-distance running, cycling, and cross-country skiing.

However, the health risks associated with exogenous EPO abuse are severe. Excessive elevation of hematocrit significantly increases blood viscosity, resistance, and cardiac workload. This hypercoagulable state can lead to thrombosis, causing life-threatening cardiovascular events such as deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke. Due to variations in EPO's half-life and duration of action depending on administration route and individual differences, abusers often struggle to precisely control red blood cell production rates, further amplifying safety risks. Multiple studies have confirmed a direct causal link between EPO abuse and sudden death in athletes.

V. Conclusion

As the sole key hormone regulating erythropoiesis in the human body, EPO plays an irreplaceable physiological role in maintaining tissue oxygenation homeostasis. Its medical applications have brought significant benefits to numerous anemia patients. However, its abuse in sports reflects a one-sided pursuit of physiological enhancement and disregard for safety boundaries. A scientific understanding of EPO's physiological functions and pathological risks is essential for standardizing its clinical use and preventing abuse. Human recombinant EPO protein, as a critical tool in basic research and preclinical development, will continue to provide foundational support for exploring EPO signaling networks.

In EPO-related basic research and signaling pathway analysis, high-quality human recombinant EPO protein is a key experimental tool. To meet this research need, Uni offers EPO Protein, Human, suitable for studies on the proliferation and differentiation of human erythroid progenitor cells, exploration of JAK2/STAT5 signaling mechanisms, and in vitro evaluation of EPO-EPOR binding activity.

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next